Literature DB >> 10520672

Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.

D Meltzer1, M Johannesson.   

Abstract

A key recommendation of the recent Panel on Cost-Effectiveness in Health and Medicine was that cost-effectiveness analyses be carried out from a societal perspective. The authors show that two of the Panel's recommendations concerning costs are not consistent with a societal perspective, and how to correct those inconsistencies. In its recommendations concerning costs resulting from morbidity, the Panel advises excluding lost income from costs in the belief that individuals take income changes into account when they respond to the quality-of-life questions that are used to calculate quality-adjusted life years (QALYs). It is shown that even if individuals do consider income changes in responding to these quality-of-life questions, this recommendation would seriously underestimate production losses due to morbidity, since individuals do not bear a major part of lost production. In its recommendations concerning costs resulting from mortality, the Panel does not require that health care costs for "unrelated" illness and non-health care consumption and production during added life years be included in the Reference Case. It is shown that omitting these costs will seriously distort comparisons of programs at different ages and favor programs that extend life over those that improve quality of life. This can be corrected by including total consumption minus production in added life-years among costs.

Mesh:

Year:  1999        PMID: 10520672     DOI: 10.1177/0272989X9901900401

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  29 in total

Review 1.  Antiviral therapies for herpes zoster infections. Are they economically justifiable?

Authors:  K J Smith; M S Roberts
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 2.  Why training is the key to successful guideline implementation.

Authors:  A D Paltiel; P J Neumann
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

3.  Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.

Authors:  Brian J Cohen
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  The relationship between productivity and health-related QOL: an exploration.

Authors:  Werner B F Brouwer; Willem-Jan Meerding; Leida M Lamers; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Productivity costs in health-state valuations : does explicit instruction matter?

Authors:  Marieke Krol; Werner Brouwer; Pedram Sendi
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 8.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

Authors:  Rena M Conti; William V Padula; Richard A Larson
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

10.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Karsten Schepelmann; Yaroslav Winter; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Veit Mylius; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.